🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Viatris partners with Unmind for employee mental health

EditorBrando Bricchi
Published 01/05/2024, 19:46
VTRS
-

PITTSBURGH - Viatris Inc. (NASDAQ: NASDAQ:VTRS), a global healthcare company, has expanded its employee wellbeing program with the introduction of Unmind, a workplace mental health resource. This initiative is part of the company's broader Elevate program, aimed at enhancing the health and happiness of its workforce.

Unmind, renowned for its mental health solutions in the workplace, is now accessible to Viatris employees and their families. The program is designed by psychologists and offers confidential resources to support individuals in managing their mental health proactively. It provides personalized tools to help with various aspects of wellbeing, including stress management, sleep improvement, and overall happiness.

The launch of Unmind aligns with Viatris' commitment to its employees' health, purpose, and growth. The company's Chief People Officer, Andrew Enrietti, emphasized the significance of mental wellbeing and the role of the Elevate program in fostering a supportive work environment. The program's principles focus on physical and mental health, meaningful engagement with the community, and personal and professional development.

According to the World Health Organization, mental health conditions like depression and anxiety increased by over 25% during the first year of the Covid-19 pandemic. This surge underscores the need for organizations to prioritize employee wellbeing. Viatris has responded by ensuring that all global colleagues have access to mental health tools and support in 2024.

Sheila Muhl, Viatris' Head of Total Rewards and Talent, highlighted the company's unique position to back its employees' health and wellbeing through the partnership with Unmind. The program's champions network, comprising about 300 volunteer colleagues, facilitates the implementation of Unmind and promotes mental health discussions within the company.

Dr. Nick Taylor, Co-founder & CEO of Unmind, expressed enthusiasm about the partnership, reflecting a shared vision of prioritizing mental health and destigmatizing workplace conversations about the subject.

Viatris, headquartered in the U.S., operates on a global scale, providing medicines to approximately 1 billion patients annually. The company's 2022 Sustainability Report offers further insights into its culture and commitment to health at every life stage.

This expansion of Viatris' wellbeing program is based on a press release statement.

InvestingPro Insights

Viatris Inc. (NASDAQ: VTRS) has not only been proactive in promoting mental health through its partnership with Unmind but also shows a strong commitment to creating shareholder value. An InvestingPro Tip indicates that management has been aggressively buying back shares, which can often signal confidence in the company's future prospects. Additionally, the company has a high shareholder yield, which combines dividend payments and share repurchases to show the total payout to shareholders. This could be particularly attractive to investors looking for companies with a shareholder-friendly capital allocation policy.

On the financial front, real-time data from InvestingPro shows that as of the last twelve months ending Q4 2023, Viatris has a market capitalization of $13.74 billion and a Price/Earnings (P/E) ratio of 9.78 when adjusted, suggesting that the stock may be undervalued relative to earnings. The company also boasts a robust gross profit margin of 43.64%, indicating effective management of production costs and strong pricing power. Moreover, Viatris has been profitable over the last twelve months, with a basic and diluted EPS of $0.05, reinforcing the company's financial stability.

For investors interested in further insights, there are additional InvestingPro Tips available that delve deeper into Viatris’ financial health and market performance. These include expectations of net income growth this year and the company's position as a prominent player in the Pharmaceuticals industry. To gain access to these valuable tips and more, visit https://www.investing.com/pro/VTRS and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 11 more InvestingPro Tips available for Viatris, providing a comprehensive analysis for informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.